Retatrutide has emerged as a new medication in the fight against obesity. This groundbreaking drug, classified as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in research studies. By activating these receptors, Retatrutide suppresses appetite, {promotesglucose regulation, and ultimately contributes to significant weight los